MULTICENTER RANDOMIZED PHASE II STUDY OF WEEKLY DOCETAXEL ALONE VERSUS WEEKLY DOCETAXEL PLUS OXALIPLATIN AS A SECOND-LINE CHEMOTHERAPY IN PATIENTS WITH ADVANCED GASTRIC CANCER: PRELIMINARY RESPONSE AND SAFETY RESULTS

    loading  Checking for direct PDF access through Ovid

Abstract

Background

Gastric cancer is a frequent malignancy with worldwide estimated incidence of 990'000 cases, representing 7.8% of all cancers in 2008. There are limited data suggesting a benefit for doublet second-line chemotherapy in advanced gastric cancer.

Methods

The eligibility criteria were patients 1) with prior exposure to cisplatin based chemotherapy and advanced or recurrent stomach cancer 2) with pathologically proven gastric adenocarcinoma, 3) with an ECOG performance status 0 to 2, 4) with measurable lesions. Each treatment cycle was consisted of docetaxel 36 mg/m2 in docetaxel mono therapy group and docetaxel 36 mg/m2, oxaliplatin 80 mg/m2 in docetaxel/oxaliplatin doublet therapy group on days 1, 8. The primary end point of this study was response rate, and secondary end points included toxicity, progression free and overall survival.

Results

Fifty two patients were enrolled; median age was 63 years; male (n = 42) and female (n = 10); docetaxel mono therapy (n = 27) and docetaxel/oxalliplatin doublet therapy (n = 25). The median number of cycles administered was 2.5 (range,1-9). Fourty eight patients were assessable for efficacy. Four partial responses, 7 stable diseases in mono therapy group (RR; 4/27, 14.8%) and 1 complete remission, 4 partial responses, 13 stable diseases in double therapy group (RR; 5/25, 20.0%) were confirmed (P = 0.198). Median progression free survival was 1.97 months in the mono therapy group and 4.93 months in doublet therapy group (P = 0.007). Median overall survival was 11.57 months in the mono therapy group and 8.13 months in doublet therapy group (P = 0.650). Grade 3 or 4 adverse events were reported in 11 of 52 patients; G3 pain were in 2 patients and G3 pneumonia was in 1 patient in mono group, G3/4 neutropenia were 5 patients in the combination group, G3 nausea, vomiting, general weakness was 1 patient each group in combination group.

Conclusions

Weekly docetaxel/oxaliplatin doublet therapy showed superior progression free survival to monotherapy group as second line therapy in cisplatin pretreated advanced gastric cancer patients.

Related Topics

    loading  Loading Related Articles